
In a recent interview with Diagnostic Imaging, Eliad Josephson discussed key attributes of the HLTH USA conference, AI trends and an ongoing shift of emphasis on the development of predictive technologies with diagnostics at center stage.
Peptide-based imaging agent developer Diatech of Londonderry, NH, has filed an investigationalnew drug (IND) application with the Food and Drug Administrationfor a new radiopharmaceutical that detects infections of unknownorigin. The agent, Tc-99m P483H,
Peptide-based imaging agent developer Diatech of Londonderry, NH, has filed an investigationalnew drug (IND) application with the Food and Drug Administrationfor a new radiopharmaceutical that detects infections of unknownorigin. The agent, Tc-99m P483H, is a technetium-99m-labeled syntheticpeptide designed to home in on infection sites where white bloodcells are elevated as the body fights infection.



